Zejula-Keytruda Combo Shows Promise in Certain Ovarian Cancer Patients in Clinical Trial

Zejula-Keytruda Combo Shows Promise in Certain Ovarian Cancer Patients in Clinical Trial
A combination of Zejula (niraparib) and Keytruda (pembrolizumab) reduced tumor size in one out of four difficult-to-treat ovarian cancer patients, Tesaro's Phase 1/2 trial revealed. The 25% response rate seen in the trial — called TOPACIO (NCT02657889) — was superior to that seen in historical controls treated with either drug alone. The study, "Phase 2 TOPACIO Data Demonstrate Activity in Platinum-Resistant and Platinum-Refractory Ovarian Cancer Patients, Regardless of Biomarker Status," was presented at the 2018 Society for Gynecologic Oncology (SGO) Annual Meeting on Women’s Cancer, held March 24-27 in New Orleans. The trial was designed to test the safety and effectiveness of Zejula plus Keytruda in patients with recurrent, platinum-resistant ovarian cancer or triple negative breast cancer. Typically, response to chemotherapy is 5-18% in patients with platinum-resistant ovarian cancer, and even lower in platinum-refractory patients. Despite the introduction of new treatment approaches, including immune checkpoint inhibitors and PARP inhibitors, response rates in these patients remain low. Indeed, patients with relapsed or refractory ovarian cancer show a 0-14% response rate to PARP inhibitors, such as Tesaro's Zejula, depending on genetic biomarkers, and 10-15% to anti-PD-1 antibodies, such as Merck's Keytruda. "Patients with platinum-resistant or platinum-refractory ovarian canc
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *